Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenic mechanisms

Silvia S. Pierangeli, Pojen P. Chen, Elena Raschi, Silvia Scurati, Chaudia Grossi, Maria Orietta Borghi, Ivan Palomo, E. Nigel Harris, Pier Luigi Meroni

Research output: Contribution to journalArticle

Abstract

Antiphospholipid antibodies (Abs) are associated with thrombosis and are a risk factor for recurrent pregnancy loss and obstetric complications in patients with the antiphospholipid syndrome. It is generally accepted that the major autoantigen for aPL Abs is β2 glycoprotein I, which mediates the binding of aPL Abs to target cells (i.e., endothelial cells, monocytes, platelets, trophoblasts, etc.) leading to thrombosis and fetal loss. This article addresses molecular events triggered by aPL Abs on endothelial cells, platelets, and monocytes and complement activation, as well as a review of the current knowledge with regard to the putative receptor(s) recognized by aPL Abs on target cells as well as novel mechanisms that involve fibrinolytic processes. A section is devoted to the description of thrombotic and inflammatory processes that lead to obstetric complications mediated by aPL Abs. Based on experimental evidence using in vitro and in vivo models, new targeted therapies for treatment and/or prevention of thrombosis and pregnancy loss in antiphospholipid syndrome are proposed.

Original languageEnglish
Pages (from-to)236-250
Number of pages15
JournalSeminars in Thrombosis and Hemostasis
Volume34
Issue number3
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Antiphospholipid Syndrome
Antibodies
Thrombosis
Obstetrics
Monocytes
Endothelial Cells
Pregnancy
Antiphospholipid Antibodies
Complement Activation
Platelet Activation
Autoantigens
Trophoblasts
Glycoproteins
Blood Platelets
Therapeutics

Keywords

  • Anti-β glycoprotein I antibodies
  • Antiphospholipid antibodies
  • Decidual cells
  • Endothelial cell activation
  • Lupus anticoagulant
  • Platelet activation
  • Pregnancy loss
  • Thrombosis
  • Trophoblast

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Antiphospholipid antibodies and the antiphospholipid syndrome : Pathogenic mechanisms. / Pierangeli, Silvia S.; Chen, Pojen P.; Raschi, Elena; Scurati, Silvia; Grossi, Chaudia; Borghi, Maria Orietta; Palomo, Ivan; Harris, E. Nigel; Meroni, Pier Luigi.

In: Seminars in Thrombosis and Hemostasis, Vol. 34, No. 3, 04.2008, p. 236-250.

Research output: Contribution to journalArticle

Pierangeli, Silvia S. ; Chen, Pojen P. ; Raschi, Elena ; Scurati, Silvia ; Grossi, Chaudia ; Borghi, Maria Orietta ; Palomo, Ivan ; Harris, E. Nigel ; Meroni, Pier Luigi. / Antiphospholipid antibodies and the antiphospholipid syndrome : Pathogenic mechanisms. In: Seminars in Thrombosis and Hemostasis. 2008 ; Vol. 34, No. 3. pp. 236-250.
@article{9fcaa4f2f867401492fd4ff1953b2fd8,
title = "Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenic mechanisms",
abstract = "Antiphospholipid antibodies (Abs) are associated with thrombosis and are a risk factor for recurrent pregnancy loss and obstetric complications in patients with the antiphospholipid syndrome. It is generally accepted that the major autoantigen for aPL Abs is β2 glycoprotein I, which mediates the binding of aPL Abs to target cells (i.e., endothelial cells, monocytes, platelets, trophoblasts, etc.) leading to thrombosis and fetal loss. This article addresses molecular events triggered by aPL Abs on endothelial cells, platelets, and monocytes and complement activation, as well as a review of the current knowledge with regard to the putative receptor(s) recognized by aPL Abs on target cells as well as novel mechanisms that involve fibrinolytic processes. A section is devoted to the description of thrombotic and inflammatory processes that lead to obstetric complications mediated by aPL Abs. Based on experimental evidence using in vitro and in vivo models, new targeted therapies for treatment and/or prevention of thrombosis and pregnancy loss in antiphospholipid syndrome are proposed.",
keywords = "Anti-β glycoprotein I antibodies, Antiphospholipid antibodies, Decidual cells, Endothelial cell activation, Lupus anticoagulant, Platelet activation, Pregnancy loss, Thrombosis, Trophoblast",
author = "Pierangeli, {Silvia S.} and Chen, {Pojen P.} and Elena Raschi and Silvia Scurati and Chaudia Grossi and Borghi, {Maria Orietta} and Ivan Palomo and Harris, {E. Nigel} and Meroni, {Pier Luigi}",
year = "2008",
month = "4",
doi = "10.1055/s-0028-1082267",
language = "English",
volume = "34",
pages = "236--250",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "3",

}

TY - JOUR

T1 - Antiphospholipid antibodies and the antiphospholipid syndrome

T2 - Pathogenic mechanisms

AU - Pierangeli, Silvia S.

AU - Chen, Pojen P.

AU - Raschi, Elena

AU - Scurati, Silvia

AU - Grossi, Chaudia

AU - Borghi, Maria Orietta

AU - Palomo, Ivan

AU - Harris, E. Nigel

AU - Meroni, Pier Luigi

PY - 2008/4

Y1 - 2008/4

N2 - Antiphospholipid antibodies (Abs) are associated with thrombosis and are a risk factor for recurrent pregnancy loss and obstetric complications in patients with the antiphospholipid syndrome. It is generally accepted that the major autoantigen for aPL Abs is β2 glycoprotein I, which mediates the binding of aPL Abs to target cells (i.e., endothelial cells, monocytes, platelets, trophoblasts, etc.) leading to thrombosis and fetal loss. This article addresses molecular events triggered by aPL Abs on endothelial cells, platelets, and monocytes and complement activation, as well as a review of the current knowledge with regard to the putative receptor(s) recognized by aPL Abs on target cells as well as novel mechanisms that involve fibrinolytic processes. A section is devoted to the description of thrombotic and inflammatory processes that lead to obstetric complications mediated by aPL Abs. Based on experimental evidence using in vitro and in vivo models, new targeted therapies for treatment and/or prevention of thrombosis and pregnancy loss in antiphospholipid syndrome are proposed.

AB - Antiphospholipid antibodies (Abs) are associated with thrombosis and are a risk factor for recurrent pregnancy loss and obstetric complications in patients with the antiphospholipid syndrome. It is generally accepted that the major autoantigen for aPL Abs is β2 glycoprotein I, which mediates the binding of aPL Abs to target cells (i.e., endothelial cells, monocytes, platelets, trophoblasts, etc.) leading to thrombosis and fetal loss. This article addresses molecular events triggered by aPL Abs on endothelial cells, platelets, and monocytes and complement activation, as well as a review of the current knowledge with regard to the putative receptor(s) recognized by aPL Abs on target cells as well as novel mechanisms that involve fibrinolytic processes. A section is devoted to the description of thrombotic and inflammatory processes that lead to obstetric complications mediated by aPL Abs. Based on experimental evidence using in vitro and in vivo models, new targeted therapies for treatment and/or prevention of thrombosis and pregnancy loss in antiphospholipid syndrome are proposed.

KW - Anti-β glycoprotein I antibodies

KW - Antiphospholipid antibodies

KW - Decidual cells

KW - Endothelial cell activation

KW - Lupus anticoagulant

KW - Platelet activation

KW - Pregnancy loss

KW - Thrombosis

KW - Trophoblast

UR - http://www.scopus.com/inward/record.url?scp=50249189294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249189294&partnerID=8YFLogxK

U2 - 10.1055/s-0028-1082267

DO - 10.1055/s-0028-1082267

M3 - Article

C2 - 18720303

AN - SCOPUS:50249189294

VL - 34

SP - 236

EP - 250

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 3

ER -